A global registry of women affected by COVID-19 in pregnancy and their babies, to guide treatment and prevention

Pregnancy and Neonatal Outcomes in COVID-19: a global registry of women with suspected COVID-19 or confirmed SARS-CoV-2 infection in pregnancy and their neonates; understanding natural history to guide treatment and prevention

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN68026880

Enrollment

1000

Registered

2020-04-30

Start date

2020-01-01

Completion date

Unknown

Last updated

2024-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 (SARS-CoV-2 infection) in pregnancy and neonates Infections and Infestations

Interventions

The study will form a global disease registry linked with other national data sources for women with suspected COVID-19 or confirmed SARS-CoV-2 in pregnancy and their neonates. Investigators can regis

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Women aged 18-50 who are pregnant and their babies 2. Suspected COVID-19 or confirmed SARs-CoV-2 infection 3. Delivery or pregnancy loss between January 2020 and March 2021

Exclusion criteria

Exclusion criteria: Individuals who do not meet the inclusion criteria

Design outcomes

Primary

Measure	Time frame
1. Confirmed SARS-CoV-2 infection in women in pregnancy or their neonates, measured using routine clinical data from 01/01/2020 to 31/03/2021 2. Suspected SARS-CoV-2 (defined as woman self-isolating for suspected COVID-19 with symptoms, symptoms will be recorded) measured using routine clinical data from 01/01/2020 to 31/03/2021	—

Secondary

Measure	Time frame
1. Incidence of miscarriage measured using routine clinical data from 01/01/2020 to 31/3/2021 2. Incidence of fetal growth restriction and stillbirth measured using routine clinical data from 01/01/2020 to 31/3/2021 3. Incidence of preterm birth measured using routine clinical data from 01/01/2020 to 31/3/2021 4. Incidence of vertical transmission to the neonate measured using routine clinical data from 01/01/2020 to 31/3/2021 5. Co-morbidities measured using routine clinical data from 01/01/2020 to 31/3/2021 6. Medical history measured using routine clinical data from 01/01/2020 to 31/3/2021 7. Details of the delivery of baby/babies measured using routine clinical data from 01/01/2020 to 31/3/2021	—

Measure

Time frame

1. Incidence of miscarriage measured using routine clinical data from 01/01/2020 to 31/3/2021 2. Incidence of fetal growth restriction and stillbirth measured using routine clinical data from 01/01/2020 to 31/3/2021 3. Incidence of preterm birth measured using routine clinical data from 01/01/2020 to 31/3/2021 4. Incidence of vertical transmission to the neonate measured using routine clinical data from 01/01/2020 to 31/3/2021 5. Co-morbidities measured using routine clinical data from 01/01/2020 to 31/3/2021 6. Medical history measured using routine clinical data from 01/01/2020 to 31/3/2021 7. Details of the delivery of baby/babies measured using routine clinical data from 01/01/2020 to 31/3/2021

—

Countries

Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Canada, Chile, Colombia, Czech Republic, Ecuador, Egypt, England, Estonia, Germany, Greece, Guatemala, Hungary, India, Indonesia, Ireland, Israel, Italy, Japan, Latvia, Lebanon, Malta, Mexico, Netherlands, Nigeria, Peru, Portugal, Qatar, Romania, Russian Federation, South Africa, Spain, Thailand, Tunisia, Uganda, United Arab Emirates, United Kingdom, United States of America

Contacts

Public ContactEdward Mullins

edward.mullins@imperial.ac.uk+44 (0)20 3313 1111

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 16, 2026